Organization and Nature of Business - Additional Information (Details) $ / shares in Units, $ in Thousands			9 Months Ended
	Aug. 25, 2020 USD ($) $ / shares shares	Aug. 20, 2020	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Organization and Nature of Business [Line Items]
Accumulated deficit | $			$ 116,080	$ 76,456
Cash, cash equivalents and marketable securities | $			$ 481,300
Reverse stock split, description			On August 20, 2020, the Board approved a 1-for-1.5949 reverse stock split of the Company’s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company’s outstanding series of preferred stock. All share and per share amounts in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
Reverse stock split		1.5949
Initial Public Offering
Organization and Nature of Business [Line Items]
Common stock shares issued | shares	9,987,520
Common stock per share | $ / shares	$ 20.00
Gross proceeds from issuance initial public offering | $	$ 199,800
Underwriters
Organization and Nature of Business [Line Items]
Common stock shares issued | shares	1,302,720
Private Placement | Vertex Pharmaceuticals Incorporated
Organization and Nature of Business [Line Items]
Common stock shares issued | shares	676,354
Common stock per share | $ / shares	$ 20.00